Testing children for anti-MOG (myelin oligodendrocyte glycoprotein) antibodies at the time of clinical onset of acquired demyelinating syndromes (ADS) could help identify a subgroup with distinct clinical and MRI features, new research suggests.
Presenting at ECTRIMS 2018, Dr Giulia Fadda of McGill University, Montreal, Canada, reported data from a study in which anti-MOG antibody status was assessed in children with incident ADS, recruited for the Canadian Demyelinating Disease Study.